MDT

100.71

0%↓

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

Начало・Списък с акции・Vaxart Inc

Vaxart Inc

Затворен

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

Ключови измерители
By Trading Economics
Приходи	6.8M -8.1M
Продажби	33M 72M
EPS	-0.04
Марж на печалбата	-11.242
Служители	105
EBITDA	6.7M -5.4M

Дивиденти
By Dow Jones
Следващи печалби	19.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	67M 158M
Предишно отваряне	0
Предишно затваряне	0

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

0.4007 / 0.4252 Подкрепа & съпротива

Vaxart Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.01.2026 г., 23:07 ч. UTC

Печалби

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

27.01.2026 г., 21:27 ч. UTC

Печалби

Texas Instruments 4Q Sales Rise, Profit Falls

27.01.2026 г., 23:55 ч. UTC

Пазарно говорене

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

27.01.2026 г., 23:47 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.01.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

27.01.2026 г., 23:39 ч. UTC

Пазарно говорене

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

27.01.2026 г., 23:20 ч. UTC

Печалби

SK Innovation: Asset-Impairment Losses Weighed on Earnings

27.01.2026 г., 23:20 ч. UTC

Печалби

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

27.01.2026 г., 23:19 ч. UTC

Печалби

SK Innovation Posts Net Loss for Second Consecutive Year

27.01.2026 г., 23:19 ч. UTC

Печалби

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

27.01.2026 г., 23:18 ч. UTC

Печалби

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

27.01.2026 г., 23:18 ч. UTC

Печалби

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

27.01.2026 г., 23:11 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

27.01.2026 г., 23:11 ч. UTC

Пазарно говорене

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

27.01.2026 г., 23:07 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

27.01.2026 г., 22:17 ч. UTC

Пазарно говорене

U.S. Dollar Slips Following Trump Comments -- Market Talk

27.01.2026 г., 22:06 ч. UTC

Печалби

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

27.01.2026 г., 21:51 ч. UTC

Печалби

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

27.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

27.01.2026 г., 21:43 ч. UTC

Печалби

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

27.01.2026 г., 21:41 ч. UTC

Печалби

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

27.01.2026 г., 21:38 ч. UTC

Печалби

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

27.01.2026 г., 21:32 ч. UTC

Печалби

Ampol: Modest Profit From F&I International in 2025

27.01.2026 г., 21:32 ч. UTC

Печалби

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

27.01.2026 г., 21:31 ч. UTC

Печалби

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

27.01.2026 г., 21:31 ч. UTC

Печалби

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

27.01.2026 г., 21:30 ч. UTC

Печалби

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

27.01.2026 г., 21:29 ч. UTC

Печалби

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

27.01.2026 г., 21:29 ч. UTC

Печалби

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

27.01.2026 г., 21:28 ч. UTC

Печалби

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Сравнение с други в отрасъла

Ценова промяна

Vaxart Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Vaxart Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.4007 / 0.4252Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.